Agenus (AGEN) Income from Continuing Operations (2010 - 2026)
Agenus' (AGEN) quarterly Income from Continuing Operations came in at 364000.0 in Q1 2026, up 101.38% year-on-year from 180748.9 in Q1 2025, and up 122.05% quarter-over-quarter from 1651000.0 in Q4 2025.
Agenus (AGEN) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Agenus' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 364000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 101.38% year-over-year to 364000.0 in Q1 2026; TTM through Mar 2026 was 38312379.0, a 81.22% increase from a year earlier, with the FY2025 full-year figure at 415080000.0, up 20.05% from the prior year.
- Income from Continuing Operations rose to 364000.0 in Q1 2026 per AGEN's latest filing, from 1651000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 364000.0 in Q1 2026 and bottomed at 68252000.0 in Q3 2024.
- The 5-year median for Income from Continuing Operations is 45165000.0 (2022), against an average of 38202370.29.
- Across the five-year window, Income from Continuing Operations plunged 871.9% in 2024 and soared 101.38% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 58053000.0 in 2022, then jumped by 91.67% to 4837000.0 in 2023, then plunged by 871.9% to 47011000.0 in 2024, then surged by 96.49% to 1651000.0 in 2025, then soared by 122.05% to 364000.0 in 2026.
- Per Business Quant, the three latest AGEN Income from Continuing Operations figures stand at 364000.0 (Q1 2026), 1651000.0 (Q4 2025), and 6971379.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Agenus | 184.05 Mn | 177.29 Mn | 33.74 Mn | 364,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 364,000.00 |
| Dec 31, 2025 | -1.65 Mn |
| Sep 30, 2025 | -6.97 Mn |
| Jun 30, 2025 | -30.05 Mn |
| Mar 31, 2025 | -26.29 Mn |
| Dec 31, 2024 | -47.01 Mn |
| Sep 30, 2024 | -68.25 Mn |
| Jun 30, 2024 | -62.48 Mn |
| Mar 31, 2024 | -63.16 Mn |
| Dec 31, 2023 | -4.84 Mn |
| Sep 30, 2023 | -46.74 Mn |
| Jun 30, 2023 | -55.07 Mn |
| Mar 31, 2023 | -55.17 Mn |
| Dec 31, 2022 | -58.05 Mn |
| Sep 30, 2022 | -42.25 Mn |
| Jun 30, 2022 | -45.17 Mn |
| Mar 31, 2022 | -36.66 Mn |
| Dec 31, 2021 | -55.27 Mn |
| Sep 30, 2021 | 133.22 Mn |
| Jun 30, 2021 | -130.07 Mn |